marked.bio

Company

Hummingbird Bioscience

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

HMBD-001 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

    Recruiting Phase 1/2 Hummingbird Bioscience Started 2025Primary completion 2027-07 NCT06956690

    ENV-501

    Locally advanced or metastatic mutated EGFR (mEGFR) NSCLC (HER3+)

    EGFR exon 19 deletion / L858RMelanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer

  2. Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

    Active, not recruiting Phase 1 Hummingbird Bioscience Started 2023Primary completion 2031-03 NCT05919537

    HMBD-001docetaxelnab-paclitaxelgemcitabine

    Arms A, B and C: Cancer harboring an NRG1 gene fusion with EGF-like domain

    NRG1 fusionNon-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor